Idiopathic pulmonary fibrosis in Taiwan – A population-based study
Chih‐Cheng Lai(National Sun Yat-sen University), Jung‐Der Wang(National Cheng Kung University Hospital), Yuan‐Horng Yan(Kuang Tien General Hospital), Nai-Chi Teng(National Health Research Institutes), Likwang Chen(National Yang Ming Chiao Tung University), Yen-Teh Chang(Fu Jen Catholic University), Ting-Ting Chao(Tri-Service General Hospital), Cheng-Ren Chen(Chia-Yi Christian Hospital), Jen-Yu Wang(Fu Jen Catholic University), Hsin-Ming Lu(National Health Research Institutes), Cheng‐Yi Wang(Fu Jen Catholic University), Hen-I Lin(Fu Jen Catholic University), Chong‐Jen Yu(National Taiwan University Hospital)
Cited by 75
Related Papers
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
|The Lancet Oncology|2015|980
Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
|Clinical Cancer Research|2015|469
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
|Journal of Clinical Oncology|2023|386
Long-term air pollution exposure and risk factors for cardiovascular diseases among the elderly in Taiwan
|Occupational and Environmental Medicine|2010|321